IPSS Risk Category Intermediate-2
Drug | Drug Name | Drug Description |
---|---|---|
DB15694 | Cedazuridine | A cytidine deaminase inhibitor coadministered with the hypomethylating agent decitabine for the treatment of variable forms of myelodysplastic syndrome (MDS). |
DB01262 | Decitabine | A chemotherapeutic pyrimidine nucleoside analogue used for the treatment of myelodysplastic syndromes (MDS) by inducing DNA hypomethylation and corresponding alterations in gene expression. |
DB12500 | Fedratinib | Fedratinib is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.[L8090,L47016] |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB00928 | Azacitidine | 1 / 2 | Completed | 1 |
DB15232 | Telaglenastat | 1 / 2 | Completed | 1 |